Expanded role will help accelerate access to stable producer cell line technology, helping to solve lentiviral vector shortages for CGT

Expanded board to enable iVexSol to advance growth strategy and address lentiviral vector shortage for CGT

Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors

Funds will be used to invest in iVexSol's next-generation lentiviral vector production platform

Viral vector manufacturing and transduction processes today are lengthy and inconsistent

Lexington, MA – (March 22, 2022) iVexSol, Inc., a lentiviral vector manufacturing company is pleased to announce the appointment of Sean Brown as Senior Vice President of Operations.

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.

A gateway to explore a next generation stable lentiviral vector manufacturing technology 

FOR IMMEDIATE RELEASE

Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics